{"DataElement":{"publicId":"5215804","version":"1","preferredName":"Urothelial Carcinoma Treatment Regimen Administered Urothelial Regimen Name","preferredDefinition":"Text name of common therapies/regimens administered for treatment of urothelial carcinoma.","longName":"5215802v1.0:5215803v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"5215802","version":"1","preferredName":"Urothelial Carcinoma Treatment Regimen Administered","preferredDefinition":"A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis). It is frequently papillary._The act of having given a substance, physical or biological factor, etc. that produces a specific effect for a clinical trial.","longName":"5215800v1.0:2233610v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"5215800","version":"1","preferredName":"Urothelial Carcinoma Treatment Regimen","preferredDefinition":"A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis). It is frequently papillary.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"C4030:C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urothelial Carcinoma","conceptCode":"C4030","definition":"A carcinoma arising from the urothelial lining of the urinary tract (bladder, renal pelvis, ureter, or urethra).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FFCC62B-A805-BC7C-E050-BB89AD430750","latestVersionIndicator":"Yes","beginDate":"2016-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-08","modifiedBy":"ONEDATA","dateModified":"2016-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FFCC62B-A813-BC7C-E050-BB89AD430750","latestVersionIndicator":"Yes","beginDate":"2016-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5215803","version":"1","preferredName":"Urothelial Regimen Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"5215803v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"3225735","version":"1","preferredName":"Cisplatin","longName":"3225735","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E93-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FFCC62B-A844-BC7C-E050-BB89AD430750","beginDate":"2016-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-08","modifiedBy":"ONEDATA","dateModified":"2016-04-08","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FFCC62B-A84E-BC7C-E050-BB89AD430750","beginDate":"2016-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-08","modifiedBy":"ONEDATA","dateModified":"2016-04-08","deletedIndicator":"No"},{"value":"Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FFCC62B-A83A-BC7C-E050-BB89AD430750","beginDate":"2016-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-08","modifiedBy":"ONEDATA","dateModified":"2016-04-08","deletedIndicator":"No"},{"value":"Gemcitabine+Paclitaxel","valueDescription":"Gemcitabine Paclitaxel Treatment Regimen","ValueMeaning":{"publicId":"5242592","version":"1","preferredName":"Gemcitabine Paclitaxel Treatment Regimen","longName":"5242592","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-C9CF-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-C9E8-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Gemcitabine+Carboplatin+Paclitaxel","valueDescription":"Gemcitabine Carboplatin Paclitaxel Treatment Regimen","ValueMeaning":{"publicId":"5242593","version":"1","preferredName":"Gemcitabine Carboplatin Paclitaxel Treatment Regimen","longName":"5242593","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-C9F7-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CA10-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Gemcitabine+Cisplatin+Paclitaxel","valueDescription":"Gemcitabine Cisplatin Paclitaxel Treatment Regimen","ValueMeaning":{"publicId":"5242594","version":"1","preferredName":"Gemcitabine Cisplatin Paclitaxel Treatment Regimen","longName":"5242594","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-CA1F-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CA38-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Paclitaxel+Carboplatin","valueDescription":"Paclitaxel Carboplatin Treatment Regimen","ValueMeaning":{"publicId":"5242595","version":"1","preferredName":"Paclitaxel Carboplatin Treatment Regimen","longName":"5242595","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-CA46-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CA5F-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Gemcitabine+Carboplatin","valueDescription":"Gemcitabine Carboplatin Treatment Regimen","ValueMeaning":{"publicId":"5242596","version":"1","preferredName":"Gemcitabine Carboplatin Treatment Regimen","longName":"5242596","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-CA6D-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CA86-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Cisplatin+Methotrexate+Vinblastine (CMV)","valueDescription":"Cisplatin Methotrexate Vinblastine Treatment Regimen (CMV)","ValueMeaning":{"publicId":"5242597","version":"1","preferredName":"Cisplatin Methotrexate Vinblastine Treatment Regimen (CMV)","longName":"5242597","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.: A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-CA95-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CAAE-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Pemetrexed","valueDescription":"Pemetrexed","ValueMeaning":{"publicId":"3237462","version":"1","preferredName":"Pemetrexed","longName":"3237462","preferredDefinition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6570-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CAB8-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Methotrexate+Carboplatin+Vinblastine (MCAVI)","valueDescription":"Methotrexate Carboplatin Vinblastine Treatment Regimen (MCAVI)","ValueMeaning":{"publicId":"5242598","version":"1","preferredName":"Methotrexate Carboplatin Vinblastine Treatment Regimen (MCAVI)","longName":"5242598","preferredDefinition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-CAC7-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CAE0-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Dose dense Gemcitabine+Cisplatin","valueDescription":"Dose Intensity Gemcitabine + Cisplatin Treatment Regimen","ValueMeaning":{"publicId":"5242599","version":"1","preferredName":"Dose Intensity Gemcitabine + Cisplatin Treatment Regimen","longName":"5242599","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.: The degree or magnitude of strength, energy, or feeling.: The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Intensity","conceptCode":"C25539","definition":"The degree or magnitude of strength, energy, or feeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-CAF1-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CB0A-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Gemcitabline+Cisplatin","valueDescription":"Cisplatin/gemcitabine Treatment Regimen","ValueMeaning":{"publicId":"3378885","version":"1","preferredName":"Cisplatin/gemcitabine Treatment Regimen","longName":"3378885","preferredDefinition":"Definition not available.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/gemcitabine","conceptCode":"C11117","definition":"Definition not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-4039-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CB1E-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Dose dense MVAC","valueDescription":"Dose Dense Cisplatin/Doxorubicin/Methotrexate/Vinblastine (MVAC)","ValueMeaning":{"publicId":"5242600","version":"1","preferredName":"Dose Dense Cisplatin/Doxorubicin/Methotrexate/Vinblastine (MVAC)","longName":"5242600v1.00","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The degree or magnitude of strength, energy, or feeling._A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder and urothelial cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intensity","conceptCode":"C25539","definition":"The degree or magnitude of strength, energy, or feeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"MVAC Regimen","conceptCode":"C63486","definition":"A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder and urothelial cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F084B9-CB2C-C1E6-E050-BB89AD430DA2","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CB45-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Methotrexate+Vinblastine+Doxorubicin+Cisplatin (MVAC)","valueDescription":"Cisplatin/Doxorubicin/Methotrexate/Vinblastine Treatment Regimen (MVAC)","ValueMeaning":{"publicId":"3379277","version":"1","preferredName":"Cisplatin/Doxorubicin/Methotrexate/Vinblastine Treatment Regimen (MVAC)","longName":"3379277v1.00","preferredDefinition":"A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder and urothelial cancer._A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MVAC Regimen","conceptCode":"C63486","definition":"A regimen consisting of methotrexate, vinblastine, doxorubicin and cisplatin used for the treatment of advanced-stage bladder and urothelial cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C5C8-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CB59-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Paclitaxel","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CB63-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Other - Specify","valueDescription":"Specify Other","ValueMeaning":{"publicId":"4888051","version":"1","preferredName":"Specify Other","longName":"4888051","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"195A90B1-87F5-D292-E050-BB89AD432B03","latestVersionIndicator":"Yes","beginDate":"2015-06-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F084B9-CB94-C1E6-E050-BB89AD430DA2","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Split-dose Cisplatin+Gemcitabine","valueDescription":"Split Dose Cisplatin Gemcitabine Treatment Regimen","ValueMeaning":{"publicId":"5242657","version":"1","preferredName":"Split Dose Cisplatin Gemcitabine Treatment Regimen","longName":"5242657","preferredDefinition":"To separate or divide into distinct parts or portions.: A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.: An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Split","conceptCode":"C54572","definition":"To separate or divide into distinct parts or portions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9898-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F0A2DB-98B1-9ED8-E050-BB89AD436E03","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"5242658","version":"1","preferredName":"Gemcitabine","longName":"5242658","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98BB-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F0A2DB-98D3-9ED8-E050-BB89AD436E03","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Vinflunine","valueDescription":"Vinflunine","ValueMeaning":{"publicId":"5242660","version":"1","preferredName":"Vinflunine","longName":"5242660","preferredDefinition":"A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinflunine","conceptCode":"C61564","definition":"A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98E1-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F0A2DB-98FA-9ED8-E050-BB89AD436E03","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Atezolizumab","valueDescription":"Atezolizumab","ValueMeaning":{"publicId":"5242662","version":"1","preferredName":"Atezolizumab","longName":"5242662","preferredDefinition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atezolizumab","conceptCode":"C106250","definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9907-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F0A2DB-9920-9ED8-E050-BB89AD436E03","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F0A2DB-992A-9ED8-E050-BB89AD436E03","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F0A2DB-9934-9ED8-E050-BB89AD436E03","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"5-fluorouracil+Mitomycin","valueDescription":"Fluorouracil Mitomycin Treatment Regimen","ValueMeaning":{"publicId":"5242663","version":"1","preferredName":"Fluorouracil Mitomycin Treatment Regimen","longName":"5242663","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.: A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9942-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31F0A2DB-995B-9ED8-E050-BB89AD436E03","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"ONEDATA","dateModified":"2016-05-03","deletedIndicator":"No"},{"value":"Avelumab","valueDescription":"Avelumab","ValueMeaning":{"publicId":"5799363","version":"1","preferredName":"Avelumab","longName":"5799363","preferredDefinition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avelumab","conceptCode":"C116870","definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B00-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5201F3A3-82DB-7BF6-E053-F662850AA1CA","beginDate":"2017-06-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-06-15","modifiedBy":"ONEDATA","dateModified":"2017-06-15","deletedIndicator":"No"},{"value":"Durvalumab","valueDescription":"Durvalumab","ValueMeaning":{"publicId":"5755432","version":"1","preferredName":"Durvalumab","longName":"5755432","preferredDefinition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFD0718-5F32-7D12-E053-F662850AD37E","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5201F3A3-82E5-7BF6-E053-F662850AA1CA","beginDate":"2017-06-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-06-15","modifiedBy":"ONEDATA","dateModified":"2017-06-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FFCC62B-A825-BC7C-E050-BB89AD430750","latestVersionIndicator":"Yes","beginDate":"2016-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":"2023.9.5 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5242953","version":"1","longName":"BCAN: Bladder Cancer Advocacy Network","context":"NCIP","ClassificationSchemeItems":[{"publicId":"5242975","version":"1","longName":"UC-GENOME","context":"NCIP"}]}],"AlternateNames":[{"name":"EXTRTREG","type":"Synonym","context":"NCIP"}],"ReferenceDocuments":[{"name":"Therapy/Regimen","type":"Preferred Question Text","description":"Therapy/Regimen","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2FFCC62B-A858-BC7C-E050-BB89AD430750","latestVersionIndicator":"Yes","beginDate":"2016-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-08","modifiedBy":"REEVESD","dateModified":"2016-05-18","changeDescription":"Curated for Bladder Cancer Advocacy Network (BCAN) UC-Genomics study.5.3.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}